Related Experiment Videos

[Lung cancer: an update in 2010]

B Besse1, S Vignot, J-C Soria

  • 1Institut Gustave-Roussy, Département de Médecine, F-94800 Villejuif, France. benjamin.besse@igr.fr

Bulletin Du Cancer
|December 24, 2009
PubMed

Insights

New data in 2009 impacts non-small cell lung cancer (NSCLC) treatment. Personalized medicine, driven by genetic mutations like EGFR and ALK, is advancing patient care and clinical trial recruitment.

Area of Science:

  • Oncology
  • Genetics
  • Clinical Trials

Background:

  • The year 2009 brought significant new data influencing therapeutic strategies for non-small cell lung cancer (NSCLC).
  • Personalized medicine approaches are increasingly relevant for NSCLC patient management.
  • Biomarkers such as EGFR mutations and EML4-ALK translocations are crucial for targeted therapies and clinical trial eligibility.

Purpose of the Study:

  • To review the impact of 2009 data on NSCLC therapeutic management.
  • To highlight the growing role of personalized medicine in NSCLC treatment.
  • To assess the utility of maintenance trials and identify areas with limited progress.

Main Methods:

  • Review of 2009 scientific literature and clinical trial data.
  • Analysis of biomarker-driven patient stratification for targeted therapies.
  • Evaluation of statistical designs and patient subsets for maintenance trials.

Main Results:

  • Personalized medicine is becoming a reality for patients with specific genetic mutations (e.g., EGFR, EML4-ALK, KRAS).
  • Maintenance trials, despite questionable designs, may benefit specific patient subsets.
  • Limited therapeutic improvements were observed in small cell lung cancer (SCLC) and locally advanced NSCLC.

Conclusions:

  • Genetic profiling is essential for tailoring NSCLC treatment and optimizing clinical trial enrollment.
  • Further research is needed to refine maintenance trial designs and improve outcomes in SCLC and locally advanced NSCLC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...